Icon
+91 94997 68112
Login Register

Biktarvy - (50 mg/200 mg/ 25 mg ; Tablets)

Bictegravir Sodium, Emtricitabine and Tenofovir Alafenamide Fumarate Gilead
50 mg/200 mg/ 25 mg ; Tablets
More Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
BIKTARVY is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of BIKTARVY.
Yes
*** *********** ******* ** *** **, ****. *** ****** ******** ******** ****** *** *** ** *** ****** *********** ** *** ****** ****** ******* ******* ** **** ** **. ******, ***** *** ***** **** **** ********* *** ******* ******** ** **** ** ****. ** ****** *** ******** ***** * **** *** ** *** ******* ******** *******. ** *** ******** ******* ****** ** ******* **** *** ****.
Biktarvy Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11
***** *** ********* *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** *** ********* **** ** *** **, **** **** ** *** **, **** ******* **** ** *** **, **** (***** ******)
****** **** *** ********* *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** *** ********* **** ** *** **, **** **** ** *** **, **** ******* **** ** *** **, **** (***** ******)
***** *** ********* *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** *** ********* **** ** *** **, **** **** ** *** **, **** ******* **** ** *** **, **** (***** ******)
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** / ********* *** **, **** ******* ******* / ******* **** *** ****** *** ****
****** **** *** / ********* *** **, **** ******* ******* / ******* ********* ******** *** ****** *** ****
***** *** / ********* *** **, **** ******* ******* / ******* **** *** ****** *** ****
  1. *** *, **** : * **** ** *** ***** *** ***** *** * *** *********.
  2. *** **, **** : ***** ******** ****** ***** *** **** ** ******.
  3. *** **, **** : ****** ******** ****** ***** *** **** ** ******.
  4. *** *, **** : ***** ******** ****** ***** *** **** ** ******.
  5. *** *, **** : ***** ******** ****** ***** *** **** ** ******.
  6. *** *, **** : ****** **** ******, ***** *** ***** ************ ** *,***,***, **,***,***, *** **,***,***.
  7. *** *, **** : ****** **** ******, ***** *** ***** ************ ** *,***,***(**** **, ****), **,***,***(**** **, ****), *** **,***,*** (*** **, ****)
  8. *** **, **** : ****** ***** ** ******* *********, ***** ******, ***** *** ***** **** ***-** ****** '*** ** ****
  9. *** **, **** : ****** ******* ********** **** ****** ** '*** (*** **) **** *****, ****** *** *****.
  10. *** **, **** : ****** ***** ******* ********* ******* ******, ***** *** ***** ************ ** *********** ** ***** ****** ****** '***.
  11. *** *, **** : ****** **** *** ********* ********.

Biktarvy - (30 mg / 120 mg / 15 mg ; Tablet)

Bictegravir Sodium, Emtricitabine and Tenofovir Alafenamide Fumarate Gilead
30 mg / 120 mg / 15 mg ; Tablet
More Than $1000 mn
None None
More Than 5
 None
None None
BIKTARVY is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of BIKTARVY.
Yes
*** *********** ******* ** *** **, ****. *** ****** ******** ******** ****** *** *** ** *** ****** *********** ** *** ****** ****** ******* ******* ** **** ** **.
Biktarvy Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7
******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *******
  1. *** **, **** : * **** ** ** ***** *** ***** ** *** ***.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.